According to Aspen Pharmacare's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.7311. At the end of 2022 the company had a P/E ratio of 8.54.
Year | P/E ratio | Change |
---|---|---|
2022 | 8.54 | -25.69% |
2021 | 11.5 | -10.96% |
2020 | 12.9 | 134.93% |
2019 | 5.49 | -61.15% |
2018 | 14.1 | -17.54% |
2017 | 17.1 | -42.29% |
2016 | 29.7 | 42.3% |
2015 | 20.9 | 40.9% |
2014 | 14.8 | -2.31% |
2013 | 15.2 | 80.85% |
2012 | 8.39 | 66.09% |
2011 | 5.05 | -19.21% |
2010 | 6.25 | 2.39% |
2009 | 6.11 | 9.39% |
2008 | 5.58 | -15.51% |
2007 | 6.61 | -8.24% |
2006 | 7.20 | -53.31% |
2005 | 15.4 | 276.11% |
2004 | 4.10 | 21.57% |
2003 | 3.37 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.